

July 1, 2025

**BSE Limited** Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001

Scrip Code No: 542665

Dear Sir/Madam,

National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

**Company Symbol: NEOGEN** 

Subject: Update on Investment in Neogen Chemicals Japan Corporation Limited - Disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

In terms of Regulation 30 read with Schedule III of Listing Regulations and our earlier communication dated March 25, 2025 and April 30, 2025, we wish to inform you that the process of registration of subscription to and allotment of 20,00,000 Equity Shares of a face value of JPY 10 each as offered and issued by the Neogen Chemicals Japan Corporation Limited ("NCL Japan") - Wholly Owned Subsidiary of the Company, constituting 100% shareholding in NCL Japan, is completed and today the company has received revised registration certificate in respect of the same from Tokyo Legal Affairs Bureau.

Further, the details pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, and SEBI circular bearing number CIR/CFD/CMD/4/2015 dated September 09, 2015, with respect to the aforesaid investment in NCL Japan by subscribing to the shares of NCL Japan is enclosed herewith as **Annexure 1** 

The information ahove is also uploaded the Company's website at being https://neogenchem.com/announcements/.

Kindly take the above information on your records.

Yours faithfully, For Neogen Chemicals Limited

Unnati Kanani **Company Secretary & Compliance Officer** Membership No: A35131

Encl.: A/a

Registered Office: 1002, Dev Corpora, Cadbury Junction, Eastern Express Highway, Thane (W) 400 601, India.

CIN No. L24200MH1989PLC050919

E: sales@neogenchem.com **W**: www.neogenchem.com

**T**: +91 22 2549 7300 **F**: +91 22 2549 7399



## ANNEXURE 1 Investment by way of subscribing to the shares of Neogen Chemicals Japan Corporation Limited.

SR. NO.	PARTICULARS	DETAILS
1	Name of the target entity, details in brief such as size, turnover etc.	Neogen Chemicals Japan Corporation Limited Wholly Owned Subsidiary of the Company (hereinafter referred to as "NCL Japan")  Authorised Capital: JPY 2,00,10,000 divided into 20,01,000 shares of JPY 10 each.  Issued share capital of the Company: JPY 2,00,01,000 divided into 20,00,100 shares of JPY 10 each.  Turnover: Not applicable as NCL Japan is yet to commence its Business Operations
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	NCL Japan is promoted by and is a wholly owned subsidiary of the Company.  The Company/ promoter/ promoter group/ group companies are interested in NCL Japan to the extent of the directorship or share capital held by the Company/ Promoter/ Promoter Group/ Group companies in the NCL Japan.
3	Industry to which the entity being acquired belongs	Specialty Chemicals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has subscribed to 20,00,000 shares at a price of JPY 10 each as offered and issued by the NCL Japan and transferred the share application money amounting to JPY 2,00,00,000 (equivalent INR 1,19,38,000) on April 30, 2025 which shall be utilised by NCL Japan for meeting its expenses or general corporate purposes or such other purposes as may be permissible under the law.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable.
6	Indicative time period for completion of the acquisition	Completed. The process of registration of subscription to and allotment of 20,00,000 shares of JPY 10 each as offered and issued by NCL Japan, constituting 100% of the shareholding in NCL Japan, is completed today and the company has received revised registration certificate in respect of the same from Tokyo Legal Affairs Bureau.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash consideration

**Registered Office**: 1002, Dev Corpora, Cadbury Junction, Eastern Express Highway, Thane (W) 400 601, India.

CIN No. L24200MH1989PLC050919

**E**: sales@neogenchem.com **W**: www.neogenchem.com

T: +91 22 2549 7300

**F**: +91 22 2549 7399



9	Cost of acquisition or the price at which the shares are acquired.  Percentage of shareholding / control acquired and / or number of shares acquired	Cost for subscribing to shares of NCL Japan is JPY 2,00,00,000 (equivalent INR 1,19,38,000).  As on date the Company holds 20,00,100 shares of JPY 10 each aggregating to JPY 2,00,01,000 constituting 100% of
		the shareholding in NCL Japan.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	NCL Japan was incorporated on July 30, 2024, to establish close co-ordination, liasioning and relationship with Japanese chemical companies. NCL Japan has presence in Japan.  Turnover of last 3 years is not applicable as it is a newly incorporated company.

Yours faithfully, For Neogen Chemicals Limited

Unnati Kanani **Company Secretary & Compliance Officer** Membership No: A35131

Registered Office: 1002, Dev Corpora, Cadbury Junction, Eastern Express Highway, Thane (W) 400 601, India.

CIN No. L24200MH1989PLC050919

E: sales@neogenchem.com W: www.neogenchem.com

**T**: +91 22 2549 7300 **F**: +91 22 2549 7399